当前位置：
X-MOL 学术
›
Bipolar Disord.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials.
Bipolar Disorders ( IF 5.0 ) Pub Date : 2020-01-07 , DOI: 10.1111/bdi.12859 Nicolas A Nunez 1 , Balwinder Singh 1 , Francisco Romo-Nava 2 , Boney Joseph 1 , Marin Veldic 1 , Alfredo Cuellar-Barboza 3 , Alejandra Cabello Arreola 1, 3 , Jennifer L Vande Voort 1 , Paul Croarkin 1 , Katherine M Moore 1 , Joanna Biernacka 1, 4 , Susan L McElroy 2 , Mark A Frye 1
Bipolar Disorders ( IF 5.0 ) Pub Date : 2020-01-07 , DOI: 10.1111/bdi.12859 Nicolas A Nunez 1 , Balwinder Singh 1 , Francisco Romo-Nava 2 , Boney Joseph 1 , Marin Veldic 1 , Alfredo Cuellar-Barboza 3 , Alejandra Cabello Arreola 1, 3 , Jennifer L Vande Voort 1 , Paul Croarkin 1 , Katherine M Moore 1 , Joanna Biernacka 1, 4 , Susan L McElroy 2 , Mark A Frye 1
Affiliation
The aim of this study was to evaluate the efficacy and safety of the dopaminergic‐enhancing agent modafinil/armodafinil (MoArm) as adjunctive treatment for bipolar depression.
中文翻译：
莫达非尼/阿莫达非辅助治疗双相抑郁症的疗效和耐受性：一项随机对照试验的荟萃分析。
这项研究的目的是评估多巴胺能增强剂莫达非尼/阿莫达非尼（MoArm）作为双相抑郁症的辅助治疗的疗效和安全性。
更新日期：2020-01-07
中文翻译：
莫达非尼/阿莫达非辅助治疗双相抑郁症的疗效和耐受性：一项随机对照试验的荟萃分析。
这项研究的目的是评估多巴胺能增强剂莫达非尼/阿莫达非尼（MoArm）作为双相抑郁症的辅助治疗的疗效和安全性。
京公网安备 11010802027423号